Corporate
New Page
New Page
Elos Medtech combines a century of expertise with a commitment to forming long-lasting partnerships that enhance lives through innovation in medical device manufacturing.
Our Purpose
Reimagining partnerships to enhance lives.
Our Mission
We deliver best-in-class technology that makes a meaningful difference for patients and customers worldwide.
Always putting quality first, we combine genuine collaboration, pioneering R&D and unrivalled expertise to drive innovation and value across the entire supply chain.
Together we create an environment where our people can flourish, empowered every day to make new advances that will change lives.
Our Vision
We are pioneers in next-generation sustainable Medtech solutions that delight our customers, advance our people, and enhance the lives of patients worldwide.
Our Values
Passionate
We are committed, determined and dedicated. With a positive attitude, we drive our development forward and find solutions.
Trustworthy
We are open and honest. We take responsibility for our actions and keep our promises.
Results-oriented
By taking the initiative and focusing on outcomes, we achieve the targets we set and create value for patients and customers.
Together
We foster a culture of collaboration in both our internal operations and in our dealings with our customers, to drive innovation and grow together.
Committed to excellence through collaboration
We pride ourselves on a century-long tradition of excellence in medical device manufacturing, underscored by enduring partnerships that thrive on collaboration and mutual growth.
With a steadfast commitment to quality, reliability, and customer satisfaction, we have forged strong relationships with industry leaders, shaping the future of healthcare with life-changing medical devices.
Our focus goes beyond mere transactions; we are dedicated to understanding and meeting the unique needs and goals of our partners, ensuring we provide solutions that not only meet but exceed expectations.
Our history is marked by over 100 years of innovation and partnership, with relationships that have lasted more than two decades, testament to our role as a trusted partner in the medical technology field. As we continue to grow and innovate, we invite you to experience the difference true partnership can make.
Let’s work together to bring your vision to life and make a lasting impact in healthcare.
Global reach meets local service
Across three continents, our 13 strategic sites are tailored to meet the diverse and dynamic needs of our customers with precision and agility.
This extensive presence enables us to navigate the complexities of the medical device industry seamlessly, ensuring comprehensive support every step of the way—from design and prototyping to manufacturing and packaging.
Our ability to adapt to market demands while upholding the highest standards of quality and reliability allows us to deliver personalized solutions that cater to your specific requirements.
We understand that success in medical device manufacturing extends beyond mere production capabilities; it requires a profound grasp of local regulations, cultural nuances, and market dynamics. Our team of seasoned experts is committed to guiding you through every stage of development, offering unmatched support and expertise.
Whether you’re cultivating a novel idea or enhancing an existing product, Elos Medtech has the resources and knowledge to transform your vision into a tangible reality, ensuring your project’s success globally.
Creating the perfect conditions for innovation
Our leadership in the medical device industry is built on a foundation of deep expertise and a commitment to innovation.
We focus on developing extensive capabilities that allow us to deliver high-quality, cutting-edge solutions across various medical technology sectors. This strategic approach ensures that we remain adaptable and responsive to the ever-evolving needs of our clients, providing them with advanced solutions that enhance healthcare outcomes.
Our success is driven by our ability to leverage the collective knowledge and innovation of our business units. Through a culture of collaboration and cross-functional teamwork, we stay at the forefront of technological advances and industry trends.
This integrated approach allows us to offer unparalleled value and service, making us the partner of choice for organizations seeking to push the boundaries of medical technology.
Looking to the future, together
Customer needs are at the heart of everything we do. We recognize that each engagement carries unique challenges and requirements.
This commitment to understanding and addressing specific demands is fundamental to our operations, fostering an environment of open communication and collaboration. Our approach ensures all stakeholders are involved and informed throughout the decision-making process, underpinning long-lasting relationships built on trust, transparency, and mutual respect.
We are dedicated to exceeding expectations by delivering tailored, innovative solutions and exceptional service. Continuous investment in our people, processes, and technologies allows us to adapt and evolve in tandem with those we serve, ensuring Elos Medtech remains a trusted partner for the long term.
Discover the difference that a customer-first approach makes in advancing medical technology with a partner truly invested in each project’s success.
Get in touch
Rights Issue – Important Notice 3
Important Information
On 12 August 2023, the board of directors of Elos Medtech AB (publ) (“Elos Medtech” or the “Company”) decided to carry out a new issue of shares of class B of up to approximately SEK 4,337 million[1] with preferential rights for the Company’s existing shareholders (the “Rights Issue”), subject to approval by an extraordinary general meeting. The purpose of the Rights Issue is to finance the acquisition of Klingel Holding GmbH (“Klingel”). The Rights Issue is fully guaranteed through a subscription and guarantee undertaking from Elos Medtech’s principal shareholder, TA Associates, through EM Intressenter AB.
Summary
- The Rights Issue is carried out to finance the acquisition of Klingel, a leading contract development and manufacturing organization (CDMO) headquartered in Germany, announced on 28 July 2023.
- The subscription price in the Rights Issue is SEK 215 per new share of class B, which corresponds to total issue proceeds of up to approximately SEK 4,337 million before deduction of transaction costs of approximately SEK 8.2 million.
- The record date for receipt of subscription rights and the right to participate in the new share issue with preferential rights is 17 October 2023. The last day of trading in the Elos Medtech share including the right to obtain subscription rights in the Rights Issue is 13 October 2023. Subscription rights will be traded on Nasdaq Stockholm from and including 20 October 2023 up to and including 31 October 2023. The board of directors is authorized to change the record date and thereby all related dates to enable receipt of the Klingel Regulatory Approvals (as defined below) for the acquisition of Klingel prior to the record date. See further “Terms of the Rights Issue“.
- The Rights Issue is fully guaranteed through a subscription and guarantee undertaking from Elos Medtech’s principal shareholder, TA Associates, through EM Intressenter AB. No compensation is paid for these commitments. Neither the subscription commitment nor the guarantee commitment is secured by bank guarantee, blocking funds, pledging or similar arrangements.
- The Rights Issue is subject to approval by the extraordinary general meeting to be held on 15 September 2023 and is conditional on merger clearance and FDI approval for the acquisition of Klingel pursuant to applicable merger control and trade laws (the “Klingel Regulatory Approvals“).
- TA Associates, through EM Intressenter AB, which as of 12 August 2023 owns 6,550,966 shares in Elos Medtech, representing approximately 81.2 per cent of the total number of shares and 65.8 per cent of the total number of votes, has undertaken to vote in favor of the Rights Issue at the forthcoming extraordinary general meeting.
Preliminary timetable for the Rights Issue[2]

Timetable 2023
_____________________________________________
[1] Since the purchase price for the acquisition of Klingel is payable in EUR, the Company has entered into currency hedging arrangements to ensure that the proceeds from the Rights Issue can be exchanged from SEK into EUR.
[2] The board of directors is authorized to change the record date and thereby all related dates to enable receipt of the Klingel Regulatory Approvals for the acquisition of Klingel prior to the record date. See further “Terms of the Rights Issue“.
Rights Issue – Important Notice 2
Important Information
Due to legal restrictions, the information on this part of the website is not accessible to certain persons. We kindly ask you to review the following information and provide the following confirmation each time you wish to access these websites. Please note that the terms set out below may be altered or updated and therefore it is important that you review them each time you visit this page.
The information in this section of the website is not intended for, and must not be accessed by, or distributed, directly or indirectly, in whole or in part, to persons resident or physically present in the United States (including its territories and provinces, any state of the United States and the District of Columbia) (the “United States”), Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, Switzerland or any other jurisdiction where such action is wholly or partially subject to legal restrictions, or would require additional prospectuses, registration or other measures than those required by Swedish law. The information on the websites does not constitute any offer regarding shares or other financial instruments in the company (“Securities”) to any person in said jurisdictions. The information on the websites may not be forwarded or reproduced in such a manner that contravenes such restrictions or gives cause to such requirements.
No Securities have been or will be registered under the United States Securities Act of 1933, as amended (the “Securities Act”) or the securities legislation or any state or other jurisdiction in the United States and may not be offered, subscribed for, used, pledged, sold, resold, allotted, delivered or otherwise transferred, directly or indirectly, in or into the United States except under an available exemption from, or in a transaction not subject to, the registration requirements under the Securities Act and in compliance with the securities legislation in the relevant state or any other jurisdiction of the United States.
No public offering of Securities is made to any country within the European Economic Area (the “EEA”) other than Sweden. In other member states of the EEA which are subject to the European Parliament and Council Regulation (EU) 2017/1129 (the “Prospectus Regulation”), such offering may be made only under the exemption in the Prospectus Regulation.
In the United Kingdom, these materials are only being distributed to, and are only directed at, and any investment or investment activity to which they relate is available only to and will be engaged in only with, “qualified investors” (within the meaning of the United Kingdom version of the EU Prospectus Regulation (2017/1129/ EU) which is part of United Kingdom law by virtue of the European Union (Withdrawal) Act 2018) who are (i) persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); (ii) high net worth entities etc. falling within Article 49(2)(a) to (d) of the Order; or (iii) such other persons to whom such investment or investment activity may lawfully be made available under the Order (all such persons together being referred to as “relevant persons”). Persons who are not relevant persons in the United Kingdom should not take any action on the basis of these materials and should not act or rely on them.
To access the information contained in this section of the website, all persons must first ensure that they are not subject to legal restrictions that limit their right to access the information on this part of the website.
We therefore kindly ask you to confirm that you are resident or physically present outside Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, Switzerland, the United States or any other jurisdiction where such action is wholly or partially subject to legal restrictions, or would require additional prospectuses, registration or other measures than those required by Swedish law, and are entitled to access the information on these websites without being subject to restrictions in any law or other regulations and without any further action being required by the company. We also kindly ask you to confirm that you have read the information, conditions and restrictions above, and confirm that you agree to comply with these.
Rights Issue – Important Notice
Important Information
The information contained in this section of the website is restricted and is not for release, publication or distribution, directly or indirectly, in whole or in part in, into or from the United States of America (including its territories and possessions, any state of the United States and the District of Columbia), Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, Switzerland or any other jurisdiction where to do so might constitute a violation of the local securities laws or regulations of such jurisdiction.
We apologize for any inconvenience this may cause. Click here to return to the homepage.
Certifications
Certifications
To ensure compliance for our products, support our customers, and meet the increasing regulatory requirements, we have RA/QA competence and experts within our company, offered through our value-adding concept, Complete Performance™.
High competence in medical device standards and regulations
We offer high competence, not only based on our long experience but also on our commitment to continuous education in medical device standards and regulations.
This ensures we are always equipped to support and guide our customers in the regulatory world, adhering to international standards and country-specific jurisdictions.
Certificates:
ISO 13485:2016
ISO 14001:2015
ISO 9001:2015
ISO 13485:2021
Product certificates for own products according to EEC/MDD 93/42
MDSAP – Elos Medtech Denmark
Our cleanrooms fulfil:
ISO 14644-1
Registration number at FDA:
Elos Medtech Pinol A/S: 3007689689
Elos Medtech Timmersdala AB: 3003847101
Elos Medtech Skara AB: 3012416874
Elos Medtech Onyx LLC: 1043653
Ruetschi Technology AG Muntelier: 3005827567
Ruetschi Technology AG Yverdon: 3014286836
Puracon GmbH Rosenheim: 3004638532
Bächler Feintech AG Hölstein: 3010287737
Klingel GmbH Pforzheim: 3004370612
Josef Ganter GmbH Dauchingen: 9680605
Download certificates here:
ISO 13485 – Memphis
EU Quality Management System Certificate – Gørløse
ISO 9001 – Gørløse
ISO 13485 – Elos Medtech AB
ISO 14001 – Elos Medtech AB
Japanese Foreign Manufacturing Certificate – Memphis
ISO 13485 – Gørløse
Japanese Foreign Manufacturing Certificate – Gørløse
EN ISO 13485 – Dauchingen
DIN EN ISO 13485 – Pforzheim
ISO 13485 – Hölstein
EN ISO 13485 – Rosenheim
ISO 9001 – Yverdon-les-Bains
Japanese Foreign Manufacturing Certificate – Muntelier
EN ISO 13485 – Muntelier
EN ISO 13485 – Renquishausen
History
Elos Medtech History
Explore over a century of innovation and excellence. Elos Medtech’s history is filled with groundbreaking achievements and strategic expansions that have established us as leaders in medical technology. Discover Our History to witness the enduring commitment and milestones that have shaped our mission to transform healthcare.
Sorry,You have not added any story yet
Corporate
Corporate responsibility
We are committed to working sustainably, aligning our actions with the interests of our stakeholders, our communities and our world through the Elos Medtech Code of Conduct. Our corporate reports, sustainability reports and our Code of Conduct are available below as printable pdf files.
View the latest Sustainability Report
Corporate Information and Investor Relations
For IR questions and information, please send an e-mail to:
Right issue 2023 – Information
AGM & EGM – Minutes & Notice to attend
EGM 2024 – Notice to Attend
EGM 2023
November – Notice to Attend | Minutes
September – Notice to Attend | Minutes
Continued General Meeting 2023 – Notice to Attend | Minutes
AGM 2023 – Notice to Attend | Minutes
AGM 2022 – Notice to Attend | Minutes
EGM 2021
December – Notice to Attend | Minutes
August – Notice to Attend | Minutes
AGM 2021 – Notice to Attend | Minutes
Remuneration Reports
Corporate Governance Reports
Corporate Governance Report 2022 (including auditors report)
Sustainability Reports
Code of Conduct
View the latest Sustainability Report
High competence in medical device standards and regulations
We offer high competence, not only based on our long experience but also on our commitment to continuous education in medical device standards and regulations.
This ensures we are always equipped to support and guide our customers in the regulatory world, adhering to international standards and country-specific jurisdictions.
Certificates:
ISO 13485:2016
ISO 14001:2015
ISO 9001:2015
ISO 13485:2021
Product certificates for own products according to EEC/MDD 93/42
MDSAP – Elos Medtech Denmark
Our cleanrooms fulfil:
ISO 14644-1
Registration number at FDA:
Elos Medtech Pinol A/S: 3007689689
Elos Medtech Timmersdala AB: 3003847101
Elos Medtech Skara AB: 3012416874
Elos Medtech Onyx LLC: 1043653
Ruetschi Technology AG Muntelier: 3005827567
Ruetschi Technology AG Yverdon: 3014286836
Puracon GmbH Rosenheim: 3004638532
Bächler Feintech AG Hölstein: 3010287737
Klingel GmbH Pforzheim: 3004370612
Josef Ganter GmbH Dauchingen: 9680605
Download certificates here:
ISO 13485 – Memphis
EU Quality Management System Certificate – Gørløse
ISO 9001 – Gørløse
ISO 13485 – Elos Medtech AB
ISO 14001 – Elos Medtech AB
Japanese Foreign Manufacturing Certificate – Memphis
ISO 13485 – Gørløse
Japanese Foreign Manufacturing Certificate – Gørløse
EN ISO 13485 – Dauchingen
DIN EN ISO 13485 – Pforzheim
ISO 13485 – Hölstein
EN ISO 13485 – Rosenheim
ISO 9001 – Yverdon-les-Bains
Japanese Foreign Manufacturing Certificate – Muntelier
EN ISO 13485 – Muntelier
EN ISO 13485 – Renquishausen